- Home
- SER vs ESLA Comparison
SER vs ESLA Comparison
Compare SER & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SER | ESLA |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 60.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SER | ESLA |
|---|---|---|
| Price | $1.54 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.00 | $8.00 |
| AVG Volume (30 Days) | ★ 98.2K | 57.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $0.73 |
| 52 Week High | $7.92 | $3.15 |
Technical Indicators
Market Signals| Indicator | SER | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 45.10 |
| Support Level | $1.53 | $1.02 |
| Resistance Level | $1.86 | $1.18 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 26.92 | 41.75 |
Price Performance
Historical ComparisonAbout SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.